Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab phase III study in active ankylosing spondylitis
NL-OMON43926Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in ankylosing spondylitis (AS) (3 arms), sponsored by Novartis. Primary endpoint: ASAS20 response at Week 16 in TNF inhibitor-naive subgroup. Started Nov 2012; status: active, not recruiting.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON43926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43926.